Using integrative genomics and functional screening, we identified coiled-coil domain containing 68 (CCDC68) as a novel putative tumor suppressor gene (TSG) in pancreatic ductal adenocarcinoma (PDAC). CCDC68 allelic losses were documented in 48% of primary PDAC patient tumors, 50% of PDAC cell lines and 30% of primary patient derived xenografts. We also discovered a single nucleotide polymorphism (SNP) variant (SNP rs1344011) that leads to exon skipping and generation of an unstable protein isoform CCDC68Δ 69-114 in 31% of PDAC patients. Overexpression of full length CCDC68 (CCDC68 wt ) in PANC-1 and Hs.766T PDAC cell lines lacking CDCC68 expression decreased proliferation and tumorigenicity in scid mice. In contrast, the downregulation of endogenous CCDC68 in MIAPaca-2 cells increased tumor growth rate. These effects were not observed with the deletion-containing isoform, CCDC68Δ 69-114 .
INTRODUCTION
Pancreatic ductal adenocarcinoma (PDAC) is the fourth leading cause of cancer-related death in North America, with a poor overall 5-year survival rate of only 5%. 1 To date, no chemotherapeutic treatments have been found to be effective against this lethal disease.
Aside from a small percentage of familial cases, PDAC is driven by the accumulation of somatic alterations. Both the loss of tumor suppressor genes (TSGs) and activation of oncogenes are involved in pancreatic carcinogenesis. Key events in pancreatic carcinogenesis that have been validated as high-frequency alterations include KRAS activating mutations and inactivation of CDKN2A, SMAD4 and p53 TSGs. 2 However, recent genome-wide surveys have demonstrated significant genetic heterogeneity among PDAC patients, with the occurrences of rare somatic mutations in many genes. [3] [4] [5] Although many of the catalogued genetic alterations can be linked to one of 12-core cancer signaling pathways, experimental evidence to verify these novel alterations as either drivers of pancreatic carcinogenesis or passengers is still lacking. In this context, we have combined integrative analysis of genome/transcriptome data with functional shRNA and ORFeome screens to identify CCDC68 as a putative TSG in PDAC.
RESULTS
Integrative genomic analysis reveals CCDC68 as a putative TSG in PDAC We have previously shown that the immortalized near-normal human pancreatic duct epithelial cell line H6c7, when transformed by KRAS G12V oncogene (H6c7-Kr), gives rise to sporadic tumors when implanted into scid mice. 6 However, H6c7-KrasT cell line rederived from one of these tumors, could now produce tumors in scid mice with 100% efficiency. We hypothesized that additional genetic alterations arose in the H6c7-KrasT cell line, which synergized with KRAS G12V oncogene to cause the full malignant transformation of H6c7 cells into invasive carcinoma. To identify genetic alterations in H6c7-KrasT cells, whole-genome tiling path array comparative genomic hybridization (aCGH) was used to compare DNA copy number between H6c7-KrasT and H6c7-Kr cells. To select for true events, only alterations with the same status in both replicates and encompassing two adjacent bacterial artificial chromosome (BAC) clones were considered. Alterations in 11 genomic regions on 9 chromosome arms were identified (Supplementary Figure S1) . The main regions included losses on chromosome 8, 15q and 18q. These regions mapped to 221 genes with gain and 2342 genes with loss.
To identify the most probable TSGs involved in the transformation of H6c7-Kr into H6c7-KrasT cells, we utilized integrative genomic analysis ( Figure 1a) . Firstly, aCGH data were integrated with aCGH and transcriptome data from 20 established PDAC cell lines. 7 The aCGH data were segmented to determine the copy number status (gain, loss or neutral) for each gene in each cell line. Then, the expression of each gene was compared between the altered and neutral samples using the Mann-Whitney U test. Genes whose expression was in the direction predicted by the copy number change and had a P-value o 0.05 were considered significant. This analysis identified 206 genes lost and underexpressed in 20 PDAC lines relative to H6c7 (Supplementary  Table S1 ). Further analysis revealed 5/206 genes (CCDC68, ARHGEF10, POLI, ME2 and CLN8) with mutation or homozygous deletion in primary PDAC patients 3 and decreased mRNA expression in at least 30% of PDAC cell lines as compared with H6c7 cells (Figure 1a) . One of the identified genes, coiled-coil domain containing 68 (CCDC68) was further investigated as a putative TSG in PDAC (bottom panel: Figure 1a ).
CCDC68 negatively affects the growth of PDAC cell lines
We assessed the proliferative effects of CCDC68 knockdown (H6c7-Kr and MIAPaca-2) and CCDC68 open reading frame (ORF) overexpression (PANC-1 cells) in PDAC cell lines using the MTS assay. Decreased CCDC68 levels significantly increased the proliferation of H6c7-Kr and MIAPaca-2 cells, whereas overexpression of CCDC68 significantly decreased the proliferation of PANC-1 cells (Figure 1b) . Using the xCELLigence platform, we confirmed the increased growth rate of MIAPaca-2 cells upon CCDC68 knockdown (Figure 1c ) and decreased the growth rate of PANC-1 cells expressing CCDC68ORF (Figure 1d) . Furthermore, the exogenous expression of CCDC68 significantly decreased soft agar colony formation of PANC-1 cells (Figure 1e ).
CCDC68 expression decreases tumorigenicity of PDAC cell lines CCDC68 was overexpressed in H6c7-KrasT, PANC-1 and Hs.766T cell lines containing undetectable endogenous CCDC68 protein (top panel: Figures 2a-c ) and the resulting cell lines and those derived from vector-only controls were injected into subcutaneous tissue of scid mice to assess tumor growth rates (Figures 2a-c) . Overexpression of CCDC68ORF in H6c7-KrasT cells completely abrogated their ability to grow tumors in mice (Figure 2a) . Furthermore, our results revealed that overexpressing CCDC68 significantly attenuated tumor growth in PANC-1 and Hs.766T xenograft models (Figures 2b and c) . The decreased tumor sizes in PANC-1 and Hs.766T xenograft models overexpressing CCDC68 were also confirmed at necropsy (Supplementary Figure S2) .
We also downregulated CCDC68 in MIAPaca-2 cells, which express CCDC68 endogenously, using two independent shRNAs targeting the 3′UTR region of the CCDC68 mRNA (top panel: Figure 2c ). The resulting cell lines were subjected to in vivo tumorigenicity assays. Downregulation of CCDC68 by two independent shRNAs increased the tumor growth rate of MIAPaca-2 cells (Figure 2c ). All MIAPaca-2 shCCDC68 xenografts showed significantly increased tumor volumes and weights compared with the shLuc2 (luciferase control) tumors (Supplementary Figure S2) . Together these results indicate that CCDC68 behaves as a TSG in PDAC xenografts.
CCDC68 protein expression is decreased in PDAC We performed CCDC68 immunohistochemistry staining on tissue microarrays created using 46 primary PDAC xenograft tissue specimens and several normal pancreas specimens. The normal interlobular and small duct epithelium consistently showed moderate cytoplasmic staining, but PDAC xenografts showed variable CCDC68 staining (Figure 3a) . Nearly 60% of PDAC cases showed lost/reduced CCDC68 protein expression as compared with normal ducts (Figure 3a) . CCDC68 was expressed in the supranuclear cytoplasm of normal duct epithelium (Figure 3b ) and well-differentiated PDAC (Figure 3c ), whereas significant loss of staining was evident in the moderately (Figure 3d ) and poorly differentiated PDAC (Figure 3e ). Some CCDC68 staining was observed in the PDX stroma; however, this staining was not seen in either normal human pancreas or PDAC (Supplementary Figure  S3) and likely represents unspecific binding of CCDC68 antibody to protein expressed by mouse fibroblasts.
CCDC68 copy number loss occurs frequently in PDAC To evaluate the role of gene deletion as a mechanism for loss of CCDC68 expression, we assessed the copy number status of Figure S4) . As there was a correlation between qPCR and FISH analysis of CCDC68 DNA copy number changes (Figure 4a ), we next assessed CCDC68 DNA copy status in 32 PDX models using qPCR. DNA copy loss was defined as values below the mean ± s.d. of qPCR derived DNA copy number in PDAC cell lines with two copies of CCDC68 DNA by FISH. We documented CCDC68 copy loss in 30% of PDX models (Supplementary Figure S4) .
To corroborate our finding of widespread copy number loss of CCDC68 in PDAC, we analyzed copy number data from 125 primary PDAC donors made available by the International Cancer Genome Consortium (ICGC, project code PACA-AU). Nearly 50% of this cohort (60/125) exhibited copy number loss of the CCDC68 gene. This rate of loss corresponded to a rank in the 91 st percentile among all genes on chromosome 18, pointing to the specificity of this particular alteration in PDAC (Supplementary Figure S5) . Figure 3 . CCDC68 protein expression is associated with differentiation status in PDAC. (a) Immunohistochemistry was performed on tissue microarrays for 46 PDAC xenografts and normal pancreas using a CCDC68 specific antibody optimized for immunohistochemistry. The graph summarizes the scoring results of all tissue microarrays as compared with expression in normal pancreatic ducts. P o0.0001, Mann-Whitney U. CCDC68 perinuclear expression was apparent on the apical side of the normal pancreatic ducts (b) and well-differentiated tumors (c). Moderately (d) and poorly (e) differentiated tumors showed random and low expression of CCDC68 protein.
We next investigated the influence of copy number loss on CCDC68 mRNA expression. mRNA expression was assessed by RT-qPCR covering two CCDC68 exons in 32 primary patientderived mouse xenograft (PDX) models and 19 PDAC cell lines. There was no significant overall correlation between copy number and mRNA expression of CCDC68 in PDAC xenografts and cell lines (Figure 4b ). However, there was an overall correlation between CCDC68 mRNA and protein expression as determined in several PDAC cell lines (Figure 4c ) and PDX models (Figure 4d ).
Novel CCDC68 alternate splice variant lacking amino acids 69-114 Although CCDC68 copy number loss occurs in 50% of PDAC, only a small subset of those patients actually showed reduced CCDC68 mRNA expression, suggesting additional regulatory mechanisms in PDAC. We hypothesized that the mutation of CCDC68 could account for loss of function in PDAC. Sequencing of CCDC68 in 19 PDAC cell lines did not reveal any somatic mutations in CCDC68. However, in the AsPC-1 cell line, we discovered a CCDC68 transcript with deletion of exon 5 ( Figure 5a ). To determine whether this was caused by mutation in the splicing site, we amplified and sequenced the 5′ donor splice site and indeed identified the c.620G4A substitution one nucleotide upstream of the exon 5 donor splice (SNP rs1344011) (Figure 5b ). PCR analysis revealed the presence of this single nucleotide polymorphism (SNP) in 31% of PDX models (10/32) suggesting that its expression might be relevant to PDAC disease (data not shown). The translation analysis of rs1344011 CCDC68 variant predicted a protein CCDC68Δ
69-114 with histidine 69-lysine 114 in-frame deletion. This smaller CCDC68Δ 69-114 protein was confirmed by western blotting in AsPC-1 as compared with 293T cells expressing exogenous CCDC68 wt and two cell lines, HPAF-II and MIAPaca-2 with high endogenous CCDC68 wt expression (Figure 5c ). NetGene2 splice site prediction software revealed that G/A substitution in SNP rs1344011 decreases the strength of the donor splice site, suggesting that exon skipping may result from this substitution (http://www.cbs.dtu.dk/services/NetGene2/). To confirm this hypothesis, we subcloned minigene cassettes containing Exon5-Intron-Exon6 with (SNP) and without (wt) the rs1344011 Correlation analysis of CCDC68 DNA copy number and CCDC68 mRNA expression in 32 primary xenografts and 19 cell lines measured using qPCR. The data represent averages of three independent experiments for each sample. (c) Western blotting using CCDC68 specific antibody confirms the mRNA expression changes in selected PDAC cell lines. (d) Correlation of CCDC68 mRNA levels with CCDC68 protein levels in PDX models. Protein expression was scored by immunohistochemistry, whereas mRNA expression was measured using qPCR. Average data in (a), (b) and (d) was plotted for each sample and represented by the Tukey boxplot. P value is calculated using Man-Whitney statistical test.
substitution into the pET01 vector and overexpressed them in 293T and NIH3T3 cells. While cells transfected with either wt or SNP minigene Exon5-Intron-Exon6 cassette expressed the fused exon5-exon6 transcript, SNP minigene-expressing cells also expressed a single exon6 transcript demonstrating the skipping of exon5 resulting from rs1344011 (Figure 5d ).
Our data indicate that although SNP rs1344011-containing AsPC-1 cells contain a single copy of CCDC68 gene, both CCDC68Δ
69-114 and CCDC68 wt are expressed in these cells. This suggests that the rs1344011 splice donor substitution does not result in the complete skipping of exon 5 in CCDC68 transcript. We hence sought to determine the ratio of the two CCDC68 splice variants in PDAC cell lines and PDX models. First, H6c7 and AsPC-1 cells were subjected to RT-qPCR analysis using CCDC68Δ 69-114 / CCDC68 wt specific primers (Figure 5e ), revealing that the rs13440011 variant accounts for~40% of CCDC68 transcripts in AsPC-1. We then tested six PDX models with detectable CCDC68Δ 69-114 mRNA expression and documented variable transcript ratios of CCDC68Δ 69-114 /CCDC68 wt (Figure 5f ). Although variable ratios of CCDC68Δ 69-114 /CCDC68 wt protein levels were also apparent in six PDX models (Figure 5g ), the levels did not correlate well with the CCDC68Δ 69-114 /CCDC68 wt transcript levels suggesting that the levels of deleted and wt CCDC68 are regulated at the posttranscriptional level.
To address this discrepancy, we compared the protein stability of CCDC68 wt and CCDC68Δ 69-114 using a protein half-life assay in the presence of the protein translational inhibitor cyclohexamide. CCDC68Δ showed significantly decreased half-life compared with CCDC68 wt , suggesting that the loss of amino acids 69-114 impairs the protein stability of CCDC68 (Supplementary Figure S6) .
CCDC68 splice variant is non-functional as a tumor suppressor
We next investigated the 'tumor suppressive' role of CCDC68Δ 69-114 variant in PDAC by overexpressing CCDC68 wt and CCDC68Δ 69-114 in PANC-1 cells and examined the effects on cellular proliferation (Supplementary Figure S7) , as well as subcutaneous and orthotopic tumor growth in scid mice (Figure  6a and b) . Although overexpression of CCDC68 wt significantly decreased in vivo and in vitro growth of PANC-1 cells compared with the empty vector controls, this tumor-suppressive effect was absent in PANC-1 cells expressing the truncated CCDC68Δ 69-114 ( Figure 6 ). These findings support the conclusion that the tumor-suppressive properties of CCDC68 are specific to the full-length isoform.
DISCUSSION
Here, we report the identification and demonstration of the tumor-suppressive role of CCDC68 in PDAC. We initially identified CCDC68 in a screen for novel TSGs synergizing with KRAS oncogene to drive malignant transformation of a near-normal human pancreatic duct epithelial cell line and its tumorsuppressive activity was confirmed in several PDAC cell line models. We showed that CCDC68 loss of function occurs through copy number loss and the expression of an unstable protein isoform, CCDC68Δ 69-114 , which lack a tumor-suppressive function. Our initial analysis revealed CCDC68 as a putative TSG whose loss of function enhanced tumor formation of H6c7-Kras cells in scid mice. Incomplete tumor penetrance of our in vitro PDAC H6c7 model (partly transformed by the KRAS oncogene) in scid mice prompted us to investigate the existence of additional genes that enhance the penetrance of this model as a result of acquired genomic alterations. 6 Thus, we compared genomic profiles of partially penetrant H6c7-Kr cells with those of completely penetrant H6c7-KrasT cells to identify such candidates. aCGH analysis revealed prominent copy number losses on chromosomes 8p, 15p and 18q in H6c7-KrasT cell lines with 100% tumor penetrance. Integration of this genomic data with transcriptome data collected from both PDAC cell lines and patient samples identified CCDC68 as the most probable candidate for enhancing the tumorigenesis of H6c7-Kr cells. This hypothesis was further strengthened by in vitro shRNA and cDNA screen that revealed CCDC68 as a negative regulator of cell proliferation in H6c7-Kr, PANC-1 and MIAPaca-2 cell lines. This prompted us to continue investigation of CCDC68 as a novel TSG in PDAC.
CCDC68 is located on the 18q chromosome arm frequently lost in PDAC. SMAD4 has been recognized as a TSG in this region and is inactivated in 50% of PDAC by homozygous deletion or mutation. However, several studies have reported homozygous deletions and loss of heterozygosity in genes telomeric of the 18q21.1 locus. [8] [9] [10] [11] [12] [13] These include ME2, ELAC1 and MEX3C on 18q21.1 and DCC, SNORA37 and MBD2 on 18q21.2. More recently, SNP analysis and exome sequencing has identified loss of heterozygosity and copy neutral loss of heterozygosity at the 18q resident genes POLI and CCDC68. 3, 13 Owing to the high frequency of genetic alterations affecting genes located downstream of SMAD4, it is likely that other TSGs on 18q in PDAC remain to be identified. This hypothesis is strengthened by the observation that introduction of an additional copy of chromosome 18 into cultured PDAC cells decreases the tumorigenic potential of these cells both in vitro and in vivo independently of SMAD4 inactivation. 14 Our results indicated that 60% of PDAC patients have decreased CCDC68 protein expression levels suggesting that the expression of CCDC68 has a negative effect on PDAC tumor biology. We also observed that CCDC68 expression associates with welldifferentiated tumors. However, as our cell line xenografts revealed no significant effect of CCDC68 on overall differentiation, it is not likely that CCDC68 itself affects the differentiation status of PDAC tumors.
First line of evidence suggesting that CCDC68 might be a tumor suppressor was reported in colorectal adenocarcinoma where correlative copy number loss and CCDC68 underexpression was observed in majority of CRC patients. 15 Although we documented copy loss of CCDC68 in half of the PDAC cell lines and PDAC patients, no significant correlation between CCDC68 copy number and mRNA expression was observed. Mismatch between mRNA and copy number variation has been reported in cancer, 16, 17 and it reflects the numerous transcriptional regulatory mechanisms, including epigenetic and/or micro-RNA silencing. For CCDC68, this requires further investigations.
An additional significant finding of our study is the identification of a novel CCDC68 splice variant devoid of tumor-suppressive function in PDAC. The truncated in-frame protein CCDC68Δ 69-114 is a result of exon skipping in patients harboring a donor splice site variant SNP rs1344011. Specifically, we determined that: (i) wt and splice variant transcripts are expressed in all SNP containing cell lines and tissues, independent of copy number; (ii) PDAC patients carrying SNP rs1344011 exhibit a variable variant/wt CCDC68 mRNA expression ratio; (iii) The CCDC68 wt /CCDC68Δ 69-114 ratio appear to be regulated at the posttranscriptional level and (iv) the protein isoform resulting from SNP rs1344011 has diminished tumor-suppressive ability in PDAC cell lines. Disregulated alternative splicing has a pivotal role in carcinogenesis. In the case of TSGs, induced overexpression of antagonistic variants in cancer is often phenotypically equivalent to loss of function and this has been shown for several tumor suppressors including PTEN, BRCA1 and TP53. [18] [19] [20] We demonstrated the absence of tumor-suppressive activity of the CCDC68 variant in PANC-1 cells, further suggesting that CCDC68Δ may functionally oppose CCDC68
wt . It remains to be investigated whether the CCDC68 tumor-suppressive function is regulated by a critical balance between wt and truncated variant CCDC68 expression in patients carrying the rs1344011 SNP.
There was a mismatch between transcript and protein CCDC68Δ 69-114 /CCDC68 wt ratios in tested PDX models suggestive of posttranscriptional regulation of CCDC68 variant levels. Several cellular mechanisms are in place to ensure the critical balance of particular proteins required for normal function including regulation of translation efficiency and protein turnover. In cancer, including PDAC, this regulatory machinery is perturbed and would result in variant protein imbalances. Comparative experiments to investigate the protein stability of CCDC68 wt and CCDC68Δ show that the stability of CCDC68 protein is in part dependent on amino acids 69-114. Hence, although PDX models 135 and 110 expressed high CCDC68Δ 69-114 /CCDC68 wt transcript ratio levels, protein stability could account for decreased ratios of translated CCDC68Δ 69-114 proteins. The variable CCDC68Δ 69-114 /CCDC68 wt ratio across PDAC could then be explained by differences in the regulation of protein turnover. In addition to differences in regulation, the loss of aa69-114 could also impact the function of CCDC68 protein. Functional properties of proteins can be dramatically altered by a series of posttranslational modifications that ultimately affect the chemical properties of proteins. Using posttranslational modification prediction tools, we have identified that several putative posttranslational modifications including lysine acetylation, SUMOylation, O-linked glycosylation, phosphorylation and ubiquitination sites are residing in the aa69-114 of CCDC68 protein (Supplementary Figure S8) . The loss of any of these sites could have significant consequences on the function and/or regulation of CCDC68. However, further exploration of the cellular function(s) of CCDC68 protein is needed to establish the impact of these posttranslational modifications on CCDC68 tumor-suppressive ability. This is the first study to describe a tumor suppressor role for CCDC68 in cancer. Previous studies of CCDC68 have been mainly descriptive. Originally named se57-1, CCDC68 has been identified as a putative tumor antigen in 21% of cutaneous T-cell lymphoma, 21 17% of renal cell 22 and 15% of colorectal carcinoma patients. 23 Simultaneously and consistent with our PDAC findings, the same studies documented dramatic losses of CCDC68 expression in the majority of patients. Downregulation of CCDC68 has also been documented in 89% of primary colorectal patients and its expression was highly correlated with the associated gene copy number. 15 These data also suggest the possibility that CCDC68 is also a novel candidate TSG in colorectal cancer. Although this hypothesis requires further biological validation, the evidence of CCDC68 loss of function in human malignancies is accumulating. TCGA catalogues CCDC68 disruption through homozygous deletions, hypermethylation and somatic mutations across many human cancer types (http://www.cbioportal.org/). Our results on the role of CCDC68 in pancreatic carcinogenesis and the accumulating evidence of CCDC68 genetic alterations in cancer provide evidence that CCDC68 is a putative tumor suppressor.
MATERIALS AND METHODS

Cell culture
PDAC cell lines used in this study were obtained and cultured as recommended by the American Type Culture Collection (Manassas, VA, USA). H6c7 cells were cultured as described previously. 24 All cell lines were STR genotyped and tested for mycoplasma.
Array comparative genomic hybridization (aCGH)
Tiling path arrays were processed as previously described. 25 CGH profiles were segmented to identify DNA copy number alterations using aCGHSmooth. Duplicate profiles for H6c7-Kr and H6c7-KrasT were compared and clones were only considered if they were altered in the same direction in both profiles. Resulting clones were compared between parental and derivative cell lines. Specific regions of gain and loss that spanned two or more adjacent clones were compiled for each derivative, and genes mapping to within these altered regions were determined.
Fluorescent in situ hybridization (FISH)
Two probes were used: internal control centromeric probe CEP18 labeled with SpG (Abbott Molecular, Des Plaines, IL, USA) and CCDC68 (RP11-108F19 BAC clone probe; TCAG, Toronto, ON, Canada). The CCDC68 probe was labeled with SpO using nick translation kit (Abbott Molecular) according to the manufacturer's protocol and hybridization was performed as described previously. 27 Slides were scored at × 63 magnification on an Imager M1 Zeiss microscope (Carl Zeiss Canada Limited, Toronto, ON, Canada) and analyzed using the MetaSystems Isis FISH Imaging v5.3 (MetaSystems, Newton, MA, USA). A minimum of 100 non-overlapping intact interphase nuclei were scored per each sample. A cutoff value of 40% was applied to identify a heterozygous loss of CCDC68 in paraffin sections and 10% cutoff value in cell suspensions.
ORFeome library and vector construction
Gateway CCDC68 ORF entry clones obtained from Human ORFeome library Version 1.1 (Fisher Scientific, Ottawa, ON, Canada) were subcloned into the pLD-puro-Ccf and pLD-puro-tGFP 28 as described previously. 29 Lentiviral shRNA knockdown CCDC68 knockdown in MiaPACA-2 was accomplished using a lentiviral shRNA method with RNAi Consortium clones: shCCDC68-1; NM_025214.1-2062s1c1 (TRCN0000129087), shCCDC68-2; NM_025214.2-1313s21c1 (TRCN0000412383). The shRNA control used was shLUC2 (GTGCCAGA GTCCTTCGATTCC). Lentiviral transduction was performed using protocols from TRC (http://www.broad.mit.edu/rnai/trc/lib).
Mutation analysis
CCDC68 ORF was amplified from cDNA transcribed from normal H6c7 cells, 19 PDAC cell lines and 31 primary xenografts using Touchdown PCR as described previously. 30 Generated PCR products (P2-F+P2-R primers) were subjected to direct sequencing using sequencing primers P2-SF and P2-SR (Supplementary Table S2 ). SNP was further confirmed with a new set of primers specifically amplifying the region in question.
Minigene assay
Genomic DNA from either H6c7 (WT) or AsPC-1 (SNP) including CCDC68 intron-exon5-intron-exon6 was amplified using primers CCDC68DELFF and CCDC68151RR (Supplementary Table S2 ). The PCR fragment was subcloned into the pET01 exon trap vector (MoBiTec, Göttingen, Germany). After sequence confirmation, 293T and NIH3T3 cells were transfected with minigene constructs. RNA was isolated and the corresponding cDNA was amplified using pET01 specific forward primer (ETprim06) and CCDC68 reverse primer (P2SR). PCR products were examined on a 2% agarose gel.
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Western analysis
Western analysis was described previously. 31 Primary antibodies used in this study were: CCDC68 (S1852; Epitomics, Burlingame, CA, USA), CCDC68 (SAB1103198; Sigma-Aldrich, St Louis, MO, USA) and β-ACTIN (A1978; Sigma-Aldrich).
Immunohistochemistry
Immunohistochemistry protocols were described previously. 32 The staining intensity of CCDC68 antibody (Sigma-Aldrich; SAB1103198,1:3000) was scored by a certified pathologist on a scale from 0 to 3 (0 = absent; 1 = low; 2 = medium; 3 = high).
DNA copy number analysis and RT-qPCR analysis qPCR was performed as described previously 31 using two control genomic markers (G64212 and D4S1193) and two sets of CCDC68-specific primers (P1-F+P2-D; 68QPCRLCM-F+68QPCRLCM-R). CCDC68 copy number was estimated using comparative CT method relative to reference controls (n = 3). Copy number changes were reported relative to median copy number changes across all the samples. Standard curve analysis was used or CCDC68Δ
69-114 and CCDC68 wt copy number estimation. cDNA was amplified using primers for CCDC68 w (E6-7F1+R1) and CCDC68Δ 69-114 (E4-6F1+R1). Standard curve was established using diluted vector DNA (pDONORCCDC68 wt and pDONORCCDC68Δ ) ranging from 30 to 3 000 000 copies. RNA isolation and assay techniques were published previously. 31 Relative quantification of qPCR data was performed using ΔΔCT method. The average Ct values for the duplicates were constructed separately for the target gene and two reference genes (RPS13 and β − ACTIN). All the primers used are listed in Supplementary Table S2 . Heatmaps were created using Integrative Genomic Viewer software. 33 xCELLigence and MTS assays MTS assays were performed as described previously. 31 Growth curves were constructed using the xCELLigence platform (ACEA Biosciences, San Diego, CA, USA). Briefly, 5000 cells were seeded per well of E-plate. Impedance was measured every 15 min for 120-144 h.
Soft agar and tumorigenic assay Soft agar assay was described previously. 34 Tumorigenicity assay was performed in scid mice using subcutaneous and orthotopic injections as described 26 in accordance with protocols approved by the Animal Care Committee of the Ontario Cancer Institute.
Meta-analysis of DNA copy number and mRNA expression of PDAC patients Copy number and mRNA expression profiling data from the Australian pancreatic cancer project (project code PACA-AU) was downloaded from the ICGC data portal (https://dcc.icgc.org). This study was chosen because of its large cohort size. Relevant data were extracted with custom parser scripts and manipulated and visualized using the R programming language.
Statistical analysis
All statistical analysis was performed using GraphPad Prism 5 (GraphPad, La Jolla, CA, USA). Statistical tests used are indicated in each figure. P values ⩽ 0.05 were considered significant.
